Zobrazeno 1 - 10
of 18
pro vyhledávání: '"G. Yu. Kharkevich"'
Autor:
A. A. Glibka, N. V. Mazurina, E. A. Troshina, K. A. Sarantseva, G. Yu. Kharkevich, M. V. Volkonskii, A. R. Elfimova
Publikováno v:
Ожирение и метаболизм, Vol 21, Iss 1, Pp 42-57 (2024)
BACKGROUND: Overweight and obesity have a significant impact on the course and results of treatment of many diseases, including cancer. One of the modern types of antitumor therapy is immune checkpoint inhibitors. Taking into account the high effecti
Externí odkaz:
https://doaj.org/article/7e0ebbaa233b4fd4bd6bf97d481edf63
Autor:
D. R. Naskhletashvili, V. A. Gorbunova, A. Kh. Bekyashev, L. V. Demidov, G. Yu. Kharkevich, S. M. Banov, I. V. Samoylenko, K. А. Baryshnikov, K. V. Orlova, I. А. Utyashev, N. N. Petenko, I. G. Markina, E. A. Moskvina, S. V. Medvedev
Publikováno v:
Опухоли головы и шеи, Vol 6, Iss 4, Pp 30-34 (2017)
The effectiveness of traditional chemotherapy (with temozolomide, fotemustine, lomustine) alone or in combination with whole brain radiotherapy in melanoma patients with cerebral metastases does not exceed 7–10 % with no significant impact on survi
Externí odkaz:
https://doaj.org/article/b2ac3cf2f6194ffca9ad2854e4269286
Autor:
L. V. Demidov, G. Yu. Kharkevich, I. V. Timofeyev, I. G. Markina, V. B. Matveev, N. A. Vetrova, L. A. Kostyakova
Publikováno v:
Onkourologiâ, Vol 2, Iss 4, Pp 15-18 (2020)
There is no standard care for metastatic renal cell carcinoma (MRCC). High and intermediate IL-2 regimens are difficult to recommend due to their high toxicity. A combination of low-dose cytokines is assumed to be effective and safe in MRCC patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::aa6f798cbb0f138748082dc1ffca71e0
https://oncourology.abvpress.ru/oncur/article/view/1146
https://oncourology.abvpress.ru/oncur/article/view/1146
Autor:
M M Konstantinova, R F Savkova, L V Demidov, V A Gorbunova, G Yu Kharkevich, N Yu Antimonik, V N Merkulov, E E Simanovich, K V Ral'chenko, O V Sbrodov
Publikováno v:
Современная онкология, Vol 11, Iss 3, Pp 70-76 (2009)
Вроссийском многоцентровом нерандомизированном клиническом исследовании, включившем 92 больных в возрасте от 20 до 82 лет с морфологичес
Externí odkaz:
https://doaj.org/article/60febdfd8d194b20aa8d152f9db665ec
Autor:
I. V. Timofeyev, A. V. Madzhuga, L. V. Demidov, O. V. Somonova, G. Yu. Kharkevich, A. L. Yelizarova
Publikováno v:
Onkourologiâ, Vol 3, Iss 1, Pp 30-32 (2020)
In experimental systems, interference with coagulation can affect tumor biology. Tumor-mediated activation of the hemostatic system has been implicated in both the formation of tumor stroma and the promotion of hematogenous metastasis. We emphasize t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::493f34cb70a1fac510e8e0a53d1a6eb5
https://oncourology.abvpress.ru/oncur/article/view/1082
https://oncourology.abvpress.ru/oncur/article/view/1082
Autor:
L V Demidov, G Yu Kharkevich
Publikováno v:
Современная онкология, Vol 2, Iss 4, Pp 116-121 (2000)
Интерфероны (ИФ) как группа сложных белков, обладающих противовирусным, противомикробным, антипролиферативными иммуномодулирующим сво
Externí odkaz:
https://doaj.org/article/d99d954acd5f49bb8f46eb3e89d9587f
Publikováno v:
Problemy endokrinologii. 67(2)
The exponential rise in the use of immune checkpoint inhibitors (Ipilimumab, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab, and Avelumab) as the new standard for cancer treatment increase the incidence the immune-related adverse events due to im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee581fe6561c45888a65c3496151169d
https://pubmed.ncbi.nlm.nih.gov/34004100
https://pubmed.ncbi.nlm.nih.gov/34004100
Autor:
D. R. Naskhletashvili, V. A. Gorbunova, A. Kh. Bekyashev, L. V. Demidov, G. Yu. Kharkevich, S. M. Banov, I. V. Samoylenko, K. А. Baryshnikov, K. V. Orlova, I. А. Utyashev, N. N. Petenko, I. G. Markina, E. A. Moskvina, S. V. Medvedev
Publikováno v:
Opuholi Golovy i Šei, Vol 6, Iss 4, Pp 30-34 (2017)
The effectiveness of traditional chemotherapy (with temozolomide, fotemustine, lomustine) alone or in combination with whole brain radiotherapy in melanoma patients with cerebral metastases does not exceed 7–10 % with no significant impact on survi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f2c99091183cc3900f076001482d908
https://doi.org/10.17650/2222-1468-2016-6-4-30-34
https://doi.org/10.17650/2222-1468-2016-6-4-30-34
Publikováno v:
Терапевтический архив, Vol 79, Iss 10, Pp 23-24 (2004)
Externí odkaz:
https://doaj.org/article/eda4aaf109054e838121532c70e25744
Publikováno v:
Onkourologiâ, Vol 5, Iss 2, Pp 36-41 (2014)
Background: High and intermediate IL-2 regimens are difficult to recommend because of great toxicity and efficacy is not sufficient. We suggest that a combination of very low-dose cytokines is effective and safe in metastatic renal cell carcinoma (MR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::b7e591569d49474b158f657f0a657253
http://oncourology.abvpress.ru/index.php/oncur/article/view/266
http://oncourology.abvpress.ru/index.php/oncur/article/view/266